In renal @entity1 rigorous blood pressure control is crucial to prevent @entity8 . For renoprotection target blood pressure depends on the severity of @entity644 before treatment. For @entity644 of 1--3g/day a mean arterial pressure of 98 mmHg provides additional benefit, whereas the target should be as low as 92 mmHg if @entity644 exceeds 3g/day. The antiproteinuric effect of antihypertensive intervention predicts renoprotection; it is therefore recommended that therapy should be titrated not only on blood pressure, but also on reduction of @entity644 . All currently available classes of antihypertensives can be used to reduce blood pressure in renal @entity1 . Interventions based on blockade of the renin-angiotensin- @entity1369 system have additional antiproteinuric, and thus renoprotective, potential. Large individual differences in therapeutic benefit are common, even for interventions of proven efficacy at group level. Studies applying different classes of drugs in the same @entity1 (rotation schedules) demonstrate that individual factors are main determinants of therapy response. Exploration of the mechanisms underlying these @entity1 factors is important to improve treatment outcome. Analysis of genetic determinants of therapy response has great potential in this respect. However, therapy response is a complex phenotype. Thus, careful study of gene-gene and gene-environment interactions will be needed in order to turn this type of knowledge into benefit for the @entity1 .

Optimal blood pressure control and antihypertensive regimens in XXXX : the potential of exploring the mechanisms of response variability.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal and cardiovascular target organ damage'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone']
@entity8 :: (MESH:D007674,Disease) :: ['hypertensive renal disease']
